Search clinical trials for: GRC 17356

Total 1178 results

Glenmark Pharmaceuticals Ltd. India
Glenmark Pharmaceuticals S.A.

Completed

A Clinical Trial to Study the Effects GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients).

Painful Diabetic Peripheral Neuropathy

India, Czech Republic, Germany, United Kingdom
Glenmark Pharmaceuticals Ltd. India
Glenmark Pharmaceuticals S.A.

Withdrawn

A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)

Painful Diabetic Neuropathy

Germany, United Kingdom
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Unknown

Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers

Healthy

China
Jonsson Comprehensive Cancer Center

Active, not recruiting

Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules

Thyroid

United States
Isabel Cristina Olegário da Costa
University of Guadalajara; University of Dublin, Trinity College; Academic Centre...

Unknown

Glass Ionomer Cement Sealant in the Prevention of Post-eruptive Fractures in Molars Affected by MIH (MIHMex)

Molar Incisor Hypomineralization

Mexico
Hyundai Pharmaceutical Co., LTD.

Completed

HDDO-1756 Bio Equivalence Study

Hyperlipidemias

Korea, Republic of
Glenmark Pharmaceuticals S.A.

Completed

To Evaluate Safety, Tolerability and Pharmacokinetics of GRC 27864 in Healthy Subjects and Elderly Healthy Subjects

Healthy

United Kingdom
Forest Laboratories

Completed

Study To Assess Efficacy and Safety of Oglemilast in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS

Healthy
Glenmark Specialty S.A.

Recruiting

A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.

Lymphoma | Advanced Solid Tumor

United States, India
Chang Gung Memorial Hospital

Completed

Influence of U-relax on Vaginal Health Promotion and HPV DNA Test Change From Positive to Negative

Human Papillomavirus | Vaginal Infection

Taiwan
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers

Healthy
Glenmark Pharmaceuticals Europe Ltd. (R&D)

Unknown

A Clinical Study of GRC 8200 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

India
Boehringer Ingelheim

Completed

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design

Diabetes Mellitus, Type 2

Canada, Croatia, Estonia, France, Germany, India, Lithuania, Mexico, Netherlands, Romania, Russian Federation, Sweden, Tunisia, Ukraine
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Australia, Canada, Czech Republic, Russian Federation, Ukraine
Oswaldo Cruz Foundation
Ministry of Health, Brazil

Terminated

Probiotics for the Prevention of Premature Birth and Neonatal Related Morbidity

Sepsis | Premature Birth | Bronchopulmonary Dysplasia | Bacterial Vaginosis | Periventricular Leukomalacia

Brazil
Yale University
National Cancer Institute (NCI)

Completed

Implementing Fit Kit Colorectal Cancer (CRC) Screening in High Risk Populations

Colorectal Cancer

United States
Genentech, Inc.

Completed

A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential

Healthy Volunteers

United States
Genentech, Inc.

Completed

A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers

Healthy Volunteer

United States
Genentech, Inc.

Completed

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

United States, Spain
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female Volunteers

Healthy
Topcon Medical Systems, Inc.

Completed

Retinal Fundus Camera Evaluation

Normal Healthy Subjects With no Known Ocular Diseases

United States
National Institute of Allergy and Infectious Diseases...
United States Department of Defense

Completed

Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults

HIV Infections

Uganda, Kenya, Tanzania
Boehringer Ingelheim

Completed

Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers

Healthy
National Institute of Allergy and Infectious Diseases...
Centers for Disease Control and Prevention; International AIDS Vaccine Initiative and other collaborators

Withdrawn

Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa

HIV Infections
University of California, San Francisco
San Francisco State University; NICOS Chinese Health Coalition

Completed

Lay Health Workers and Colorectal Cancer Screening Among Chinese Americans

Colorectal Neoplasms

United States
Tel Aviv University
Wolfson Medical Center

Completed

Effects of Red Grape Cells (RGC) Powder in Type 2 Diabetics (RGC-T2D)

Type 2 Diabetes

Israel
Lawson Health Research Institute
Ontario Neurotrauma Foundation

Terminated

Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury

Urinary Tract Infections | Spinal Cord Injury

Canada
National Institute of Allergy and Infectious Diseases...
HIV Vaccine Trials Network

Completed

Safety of and Immune Response to a DNA HIV Vaccine Followed By Boosting With One of Two Serotypes of Adenoviral Vector HIV Vaccine in Healthy Adults

HIV Infections

United States
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers

Healthy
Haukeland University Hospital

Completed

Hypertonic Saline-hetastarch in Cardiac Surgery (HH)

Postoperative Cardiorespiratory Failure

Norway
University of Washington
United States Department of Defense

Recruiting

Effectiveness of Frontal Plane Adaptability in a Novel Foot Prosthesis

Amputation

United States
Mount Sinai Hospital, Canada
Canadian Institutes of Health Research (CIHR)

Withdrawn

Effect of Probiotic Lactobacilli on Vaginal Flora of Pregnant Women at High Risk for Preterm Delivery

Premature Birth | Bacterial Vaginosis

Canada
University of Pennsylvania

Recruiting

Improving the Organizational Social Context to Address Structural Racism and Discrimination

HIV/AIDS

United States
Genentech, Inc.

Completed

An Absolute Bioavailability Study in Healthy Participants Comparing Oral to Intravenous Administration of GDC-0973 (Cobimetinib)

Healthy Volunteers
Postgraduate Institute of Dental Sciences Rohtak

Completed

Effect of Intraorifice Barrier on Healing of Apical Periodontitis

Apical Periodontitis
Stanford University
National Cancer Institute (NCI); University Hospitals Cleveland Medical Center

Completed

Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

Recurrent Skin Cancer | Basal Cell Carcinoma of the Skin

United States
National Cancer Institute (NCI)

Completed

Evaluation of Food Effect on Pharmacokinetics of Vismodegib

Malignant Neoplasm

United States
Genentech, Inc.

Completed

Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects

Cancer

United States
Genentech, Inc.

Completed

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-9545 Following a Single Oral Dose (Part 1) and to Evaluate the Absolute and Relative Bioavailability of Oral Capsule Formulations of GDC-9545 (Part 2) in Healthy Female Subjects of Non-Childbearing Potential

Healthy Volunteers

United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers

Healthy
Baylor College of Medicine
Lawson Health Research Institute; Chr Hansen

Unknown

Bacteriuria Eradication Through Probiotics (BERP)

Bacteriuria

United States
Camlin Ltd
Università Politecnica delle Marche

Completed

At Home REhabilitation and Monitoring of People in poST-covid Condition Through ARc-inTellicare Platform (RESTART/RICOMINCIARE) (RICOMINCIARE)

Parkinson Disease | Post-COVID19

Italy
Genentech, Inc.

Completed

A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Solid Cancers
Genentech, Inc.

Completed

A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma, Solid Cancers

United States, United Kingdom
Genentech, Inc.

Completed

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Non-Hodgkin's Lymphoma, Solid Cancers

United Kingdom

3

Subscribe